Stock analysts at Guggenheim initiated coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a research report issued on Tuesday. The brokerage set a “neutral” rating and a $8.50 price target on the stock. Guggenheim’s price target indicates a potential upside of 8.83% from the stock’s previous close.
ENDP has been the subject of a number of other reports. Zacks Investment Research raised shares of Endo International from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research note on Wednesday, October 11th. Mizuho reaffirmed a “buy” rating and issued a $14.00 price objective (down from $19.00) on shares of Endo International in a research note on Tuesday, September 12th. Royal Bank of Canada lowered their price objective on shares of Endo International from $9.00 to $8.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. ValuEngine lowered shares of Endo International from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Goldman Sachs Group initiated coverage on shares of Endo International in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 price objective for the company. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $11.48.
Shares of Endo International (NASDAQ:ENDP) traded down $0.07 on Tuesday, hitting $7.81. 3,864,900 shares of the stock were exchanged, compared to its average volume of 7,095,765. The stock has a market capitalization of $1,740.00, a price-to-earnings ratio of 1.63, a P/E/G ratio of 2.15 and a beta of 0.59. Endo International has a 1 year low of $5.77 and a 1 year high of $17.99. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million during the quarter, compared to analyst estimates of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business’s revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.01 earnings per share. equities analysts forecast that Endo International will post 3.67 EPS for the current year.
Institutional investors have recently made changes to their positions in the business. Blair William & Co. IL bought a new position in Endo International in the second quarter worth about $126,000. LMR Partners LLP acquired a new position in shares of Endo International during the third quarter valued at about $148,000. Point View Wealth Management Inc. increased its holdings in shares of Endo International by 16.6% during the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after acquiring an additional 1,900 shares in the last quarter. Riverhead Capital Management LLC increased its holdings in shares of Endo International by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after acquiring an additional 5,887 shares in the last quarter. Finally, Bank of Hawaii acquired a new position in shares of Endo International during the second quarter valued at about $180,000. Institutional investors and hedge funds own 93.17% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Endo International (ENDP) Now Covered by Guggenheim” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/12/14/endo-international-endp-now-covered-by-guggenheim.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Thank you for taking the time to read this article. I hope you like it